Beth Karlan, M.D.

Work Titles
UCLA Professor, Obstetrics and Gynecology Member, JCCC Signal Transduction and Therapeutics Program Area

Contact Information:

Work Email Address:

Work Phone Number:

(310) 423-3302

Work Address:

8700 Beverly Blvd.
1720 S Tower(Cedars), Suite 160W, Los Angeles, CA 90048

Detailed Biography:

Dr. Karlan is nationally renowned leader in the diagnosis and treatment of women's reproductive cancers. She is referred complex and difficult cases from around the country. She is one of the four gynecologic oncologistsheading the international referral and treatment program for Ovarian Cancerat the Cedars-Sinai Comprehensive Cancer Center. Dr. Karlan is a recipientof numerous awards and honors for excellence in the fields of cancer treatmentand research. She is the Director of Gynecologic Oncology at Cedars-SinaiMedical Center, and has published over 80 articles, books and abstracts.She also serves as the Director of the Gilda Radner Ovarian Detection Programat Cedars-Sinai Medical Center. A noted speaker, Dr. Karlan has spokenas guest lecturer at medical centers and conventions throughout the world.She serves as an editorial consultant and reviewer for numerous cancer and obstetrics and gynecology journals, including the Journal of Women'sHealth and Gynecologic Oncology.


A selected list of publications:

Lin De-Chen, Xu Liang, Ding Ling-Wen, Sharma Arjun, Liu Li-Zhen, Yang Henry, Tan Patrick, Vadgama Jay, Karlan Beth Y, Lester Jenny, Urban Nicole, Schummer Michèl, Doan Ngan, Said Jonathan W, Sun Hongmao, Walsh Martin, Thomas Craig J, Patel Paresma, Yin Dong, Chan Daniel, Koeffler H Phillip   Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers Proceedings of the National Academy of Sciences of the United States of America, 2013; 110(15): 6109-14.
Singh Krishna, Lester Jenny, Karlan Beth, Bresee Catherine, Geva Tali, Gordon Ora   Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers American journal of obstetrics and gynecology, 2013; 208(4): 329.e1-6.
Monk Bradley J, Lambrechts Sandrina, Minion Lindsey, Devoogdt Nele, Karlan Beth Y, Vergote Ignace B   Incidence and management of edema associated with trebananib (AMG 386) Gynecologic oncology, 2013; .
Diaz Elena S, Karlan Beth Y, Li Andrew J   Obesity-associated adipokines correlate with survival in epithelial ovarian cancer Gynecologic oncology, 2013; 129(2): 353-7.
Painovich Jeannette M, Shufelt Chrisandra L, Azziz Ricardo, Yang Yuching, Goodarzi Mark O, Braunstein Glenn D, Karlan Beth Y, Stewart Paul M, Merz C Noel Bairey   A pilot randomized, single-blind, placebo-controlled trial of traditional acupuncture for vasomotor symptoms and mechanistic pathways of menopause Menopause (New York, N.Y.), 2012; 19(1): 54-61.
Diaz Elena S, Karlan Beth Y, Li Andrew J   Impact of beta blockers on epithelial ovarian cancer survival Gynecologic oncology, 2012; 127(2): 375-8.
Kaye Stan B, Lubinski Jan, Matulonis Ursula, Ang Joo Ern, Gourley Charlie, Karlan Beth Y, Amnon Amit, Bell-McGuinn Katherine M, Chen Lee-May, Friedlander Michael, Safra Tamar, Vergote Ignace, Wickens Mark, Lowe Elizabeth S, Carmichael James, Kaufman Bella   Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012; 30(4): 372-9.
Karlan Beth Y, Oza Amit M, Richardson Gary E, Provencher Diane M, Hansen Vincent L, Buck Martin, Chambers Setsuko K, Ghatage Prafull, Pippitt Charles H, Brown John V, Covens Allan, Nagarkar Raj V, Davy Margaret, Leath Charles A, Nguyen Hoa, Stepan Daniel E, Weinreich David M, Tassoudji Marjan, Sun Yu-Nien, Vergote Ignace B   Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012; 30(4): 362-71.
Zajchowski Deborah A, Karlan Beth Y, Shawver Laura K   Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas Molecular cancer therapeutics, 2012; 11(2): 492-502.
Fleming Nicole D, Agadjanian Hasmik, Nassanian Hoorig, Miller Carl W, Orsulic Sandra, Karlan Beth Y, Walsh Christine S   Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer Cancer, 2012; 118(3): 689-97.
Fleming Nicole D, Cass Ilana, Walsh Christine S, Karlan Beth Y, Li Andrew J   CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer Gynecologic oncology, 2011; 121(2): 249-52.
Chien Wenwen, O'Kelly James, Lu Daning, Leiter Amanda, Sohn Julia, Yin Dong, Karlan Beth, Vadgama Jay, Lyons Karen M, Koeffler H Phillip   Expression of connective tissue growth factor (CTGF/CCN2) in breast cancer cells is associated with increased migration and angiogenesis International journal of oncology, 2011; 38(6): 1741-7.
Fleming Nicole D, Lentz Scott E, Cass Ilana, Li Andrew J, Karlan Beth Y, Walsh Christine S   Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma? Gynecologic oncology, 2011; 120(2): 189-92.
Fejzo Marlena S, Ginther Chuck, Dering Judy, Anderson Lee, Venkatesan Natarajan, Konecny Gottfried, Karlan Beth, Slamon Dennis J   Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK Genes, chromosomes & cancer, 2011; 50(6): 434-41.
Zhu Min, Saxton Romaine E, Ramos Lillian, Chang David D, Karlan Beth Y, Gasson Judith C, Slamon Dennis J   Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis Molecular cancer therapeutics, 2011; 10(8): 1500-8.
Zhang Lei, Xiao Hua, Karlan Scott, Zhou Hui, Gross Jenny, Elashoff David, Akin David, Yan Xinmin, Chia David, Karlan Beth, Wong David T   Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer PloS one, 2010; 5(12): e15573.
Cass Ilana, Walts Ann, Karlan Beth Y   Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? Gynecologic oncology, 2010; 117(1): 27-31.
Ioffe Yevgeniya J M, Elmore R Geoffrey, Karlan Beth Y, Li Andrew J   Effect of cigarette smoking on epithelial ovarian cancer survival The Journal of reproductive medicine, 2010; 55(7-8): 346-50.
Li Andrew J, McAllister Paula, Karlan Beth Y   Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers Gynecologic oncology, 2010; 116(1): 105-8.
Walsh Christine S, Blum Audra, Walts Ann, Alsabeh Randa, Tran Hang, Koeffler H Phillip, Karlan Beth Y   Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening Gynecologic oncology, 2010; 116(3): 516-21.
Walsh Christine S, Karlan Beth Y   Molecular signatures of ovarian cancer: from detection to prognosis Molecular diagnosis & therapy, 2010; 14(1): 13-22.
Cass Ilana, Karlan Beth Y   Ovarian cancer symptoms speak out--but what are they really saying? Journal of the National Cancer Institute, 2010; 102(4): 211-2.
Karam Amer K, Karlan Beth Y   Ovarian cancer: the duplicity of CA125 measurement Nature reviews. Clinical oncology, 2010; 7(6): 335-9.
Zhu Min, Fejzo Marlena S, Anderson Lee, Dering Judy, Ginther Charles, Ramos Lillian, Gasson Judith C, Karlan Beth Y, Slamon Dennis J   Periostin promotes ovarian cancer angiogenesis and metastasis Gynecologic oncology, 2010; 119(2): 337-44.
Mercado Cheryl, Zingmond David, Karlan Beth Y, Sekaris Evan, Gross Jenny, Maggard-Gibbons Melinda, Tomlinson James S, Ko Clifford Y   Quality of care in advanced ovarian cancer: the importance of provider specialty Gynecologic oncology, 2010; 117(1): 18-22.
Li Andrew J, Elmore R Geoffrey, Chen Ida Yii-der, Karlan Beth Y   Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers Gynecologic oncology, 2010; 116(1): 78-81.
Karam Amer K, Chiang Jing Wang, Fung Ewina, Nossov Vladimir, Karlan Beth Y   Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer Gynecologic oncology, 2009; 114(2): 246-52.
Li Andrew J, Scoles Daniel R, Armstrong Klara U M, Karlan Beth Y   Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas Gynecologic oncology, 2008; 109(2): 220-5.
Li Andrew J, Karlan Beth Y   Androgens and epithelial ovarian cancer: What's the connection? Cancer biology & therapy, 2008; 7(11): 1712-6.
Fejzo Marlena S, Dering Judy, Ginther Chuck, Anderson Lee, Ramos Lilian, Walsh Christine, Karlan Beth, Slamon Dennis J   Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target Genes, chromosomes & cancer, 2008; 47(10): 873-83.
Wakimoto Naoki, Yin Dong, O'Kelly James, Haritunians Talin, Karlan Beth, Said Jonathan, Xing Hongtao, Koeffler H Phillip   Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo Cancer science, 2008; 99(9): 1793-7.
Walsh Christine S, Ogawa Seishi, Karahashi Hisae, Scoles Daniel R, Pavelka James C, Tran Hang, Miller Carl W, Kawamata Norihiko, Ginther Charles, Dering Judy, Sanada Masashi, Nannya Yasuhito, Slamon Dennis J, Koeffler H Phillip, Karlan Beth Y   ERCC5 is a novel biomarker of ovarian cancer prognosis Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008; 26(18): 2952-8.
O'Kelly James, Chung Alice, Lemp Nathan, Chumakova Katya, Yin Dong, Wang He-Jing, Said Jonathan, Gui Dorina, Miller Carl W, Karlan Beth Y, Koeffler H Phillip   Functional domains of CCN1 (Cyr61) regulate breast cancer progression International journal of oncology, 2008; 33(1): 59-67.
Walsh Christine S, Ogawa Seishi, Scoles Daniel R, Miller Carl W, Kawamata Norihiko, Narod Steven A, Koeffler H Phillip, Karlan Beth Y   Genome-wide loss of heterozygosity and uniparental disomy in BRCA1/2-associated ovarian carcinomas Clinical cancer research : an official journal of the American Association for Cancer Research, 2008; 14(23): 7645-51.
Elmore R Geoffrey, Ioffe Yevgeniya, Scoles Daniel R, Karlan Beth Y, Li Andrew J   Impact of statin therapy on survival in epithelial ovarian cancer Gynecologic oncology, 2008; 111(1): 102-5.
Walsh Christine S, Miller Carl W, Karlan Beth Y, Koeffler H Phillip   Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk Gynecologic oncology, 2007; 104(3): 660-4.
Pavelka James C, Li Andrew J, Karlan Beth Y   Hereditary ovarian cancer--assessing risk and prevention strategies Obstetrics and gynecology clinics of North America, 2007; 34(4): 651-65, vii-viii.
Wolf Ido, O'Kelly James, Wakimoto Naoki, Nguyen Anh, Amblard Franck, Karlan Beth Y, Arbiser Jack L, Koeffler H Phillip   Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest International journal of oncology, 2007; 30(6): 1529-37.
Li Andrew J, Elmore R Geoffrey, Pavelka James C, Karlan Beth Y   Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology Gynecologic oncology, 2007; 107(3): 420-3.
Karlan Beth Y, Berchuck Andrew, Mutch David   The role of genetic testing for cancer susceptibility in gynecologic practice Obstetrics and gynecology, 2007; 110(1): 155-67.
Wolf Ido, Bose Shikha, Desmond Julian C, Lin Bryan T, Williamson Elizabeth A, Karlan Beth Y, Koeffler H Phillip   Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer Breast cancer research and treatment, 2007; 105(2): 139-55.
Liede A, Karlan BY, Narod SA   Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature J Clin Oncol, 2004; 22(4): 735-42.
Karlan BY   Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis Gynecologic oncology. , 2004; 92(2): 519-20.
Karlan BY   The colon is a pelvic organ too: taking the Couric challenge Obstet Gynecol, 2004; 104(5 Pt 1): 907-9.
Li AJ, Madden AC, Cass I, Leuchter RS, Lagasse LD, Karlan BY   The prognostic significance of thrombocytosis in epithelial ovarian carcinoma Gynecologic oncology. , 2004; 92(1): 211-4.
Li AJ, Baldwin RL, Karlan BY   Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures American journal of obstetrics and gynecology. , 2003; 189(1): 22-7.
Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY   Improved survival in women with BRCA-associated ovarian carcinoma Cancer. , 2003; 97(9): 2187-95.
Baldwin RL, Tran H, Karlan BY   Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor beta growth arrest independent of transforming growth factor beta/Smad signaling Cancer research. , 2003; 63(6): 1413-9.
Chen LM, Yamada SD, Fu YS, Baldwin RL, Karlan BY   Molecular similarities between primary peritoneal and primary ovarian carcinomas International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. , 2003; 13(6): 749-55.
Urban N, McIntosh MW, Andersen M, Karlan BY   Ovarian cancer screening Hematol Oncol Clin North Am, 2003; 17(4): 989-1005, ix.
Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon DJ   Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells Cancer research. , 2003; 63(1): 196-206.
Li AJ, Baldwin RL, Karlan BY   Short androgen receptor allele length is a poor prognostic factor in epithelial ovarian carcinoma Clinical cancer research : an official journal of the American Association for Cancer Research. , 2003; 9(10 Pt 1): 3667-73.
Li AJ, Karlan BY   Surgical advances in the treatment of ovarian cancer Hematol Oncol Clin North Am, 2003; 17(4): 945-56.

Does this profile need updating? Contact Us